Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
$47.55
$47.31
$15.08
$47.90
$2.27B1.031.03 million shsN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$153.66
-0.5%
$159.39
$140.68
$169.99
$370.29B0.497.97 million shs10.72 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$756.55
+0.3%
$832.96
$677.09
$972.53
$717.34B0.513.39 million shs2.44 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$78.28
-1.1%
$88.03
$75.96
$134.63
$197.75B0.411.58 million shs16.04 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
0.00%0.00%0.00%0.00%0.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.62%+2.40%-5.44%+6.50%+4.45%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.00%+4.36%-7.38%+1.45%+0.25%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.18%-2.60%-16.60%-20.76%-37.17%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.778 of 5 stars
3.35.04.23.93.32.50.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9192 of 5 stars
4.43.03.34.02.72.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9993 of 5 stars
4.33.05.03.92.53.33.8
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
0.00
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.61
Moderate Buy$171.5011.61% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,012.0033.76% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.64
Moderate Buy$115.5047.54% Upside

Current Analyst Ratings Breakdown

Latest LLY, DICE, JNJ, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.00
4/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$973.00 ➝ $928.00
4/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.00
4/9/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.00
4/9/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$157.00 ➝ $172.00
4/9/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,146.00 ➝ $1,124.00
4/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00
4/2/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/2/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
$1.13M2,008.50N/AN/A$10.86 per share4.38
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.17$12.63 per share12.17$29.69 per share5.18
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.93$12.33 per share61.34$15.05 per share50.27
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.08$2.72 per share28.82$14.85 per share5.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
-$83.89M-$2.34N/AN/AN/AN/A-22.01%-20.79%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$6.6523.1113.882.5618.20%34.24%13.63%4/15/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7164.6124.311.4023.51%85.24%16.19%5/1/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7311.637.910.7726.67%45.35%17.36%4/24/2025 (Estimated)

Latest LLY, DICE, JNJ, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
1/22/2025Q4 2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.23%+5.43%74.59%63 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.79%+15.21%51.24%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.14%+5.73%48.14%14 Years

Latest LLY, DICE, JNJ, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20256/10/2025
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/A
25.88
32.44
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15

Institutional Ownership

CompanyInstitutional Ownership
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
4.90%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
7147.73 million45.39 millionNot Optionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable

Recent News About These Companies

6MRK : Price Over Earnings Overview: Merck & Co
The Zacks Analyst Blog Merck and AbbVie
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DICE Therapeutics stock logo

DICE Therapeutics NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$153.66 -0.71 (-0.46%)
Closing price 03:59 PM Eastern
Extended Trading
$153.62 -0.03 (-0.02%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$756.55 +2.20 (+0.29%)
Closing price 03:59 PM Eastern
Extended Trading
$758.82 +2.27 (+0.30%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$78.28 -0.89 (-1.12%)
Closing price 03:59 PM Eastern
Extended Trading
$78.22 -0.06 (-0.07%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.